About the company
iana Therapeutics is a clinical development-stage company led by an experienced team developing new therapies within ophthalmology and with an initial focus on Diabetic Retinopathy.
Diabetic Retinopathy is a serious condition that afflicts 30% of patients with diabetes and leads to vision loss and blindness. Ciana is a spin-out from a pharmaceutical company that originally developed their lead drug therapy, Danegaptide. Danegaptide has a proven safety profile in humans, strong efficacy in pre-clinical therapeutic models and can uniquely address the need for more effective and earlier treatments in Diabetic Retinopathy.
Experienced Team with Valuable Expertise
Key personnel, advisors and directors already identified
Med. Dir. for 11 years including US expatriation to Princeton, NJ.
Directors
Bernard E. Lyons, PhD.
Former CEO of three medical device companies
Harold Van Wart, PhD.
Former CEO of two therapeutics companies
Scientific Advisors
Prof. Carl Regillo, MD, (Wills, TJU)
Dr. Jeffrey S. Heier, MD (OCB)
Prof. Schlingemann, MD, PhD (AMC)
Prof. Michael Larsen, MD, DMSc (RH)
Prof. Sayon Roy, PhD, FARVO (BMC)
Additional Team
Senior CMC advisors contracted
Toxicology consultant contracted
Regulatory advisor
VP / Director Finance, part time
Director R&D
Leading CDMO vendors